Benitec Biopharma Inc.

Equities

BNTC

US08205P2092

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-16 EDT			5-day change	1st Jan Change
10.41 ^USD	+2.06%		+12.91%	+222.29%

07-15	Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-Dose BB-301 in Phase 1b/2a Study	CI
07-01	Benitec Biopharma Inc. Announces Appointment of Kishen Mehta to Its Board of Directors	CI

Benitec Biopharma Limited Announces Cash Flow Results for the Second Quarter and Six Months Ended December 31, 2015

January 29, 2016 at 06:50 am

Benitec Biopharma Limited announced cash flow results for the second quarter and six months ended December 31, 2015. For the quarter, the company reported net operating cash out flow was AUD 7,036,000.

For the period, the company reported net operating cash out flow was AUD 14,169,000.

Latest news about Benitec Biopharma Inc.

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-Dose BB-301 in Phase 1b/2a Study	07-15	CI
Benitec Biopharma Inc. Announces Appointment of Kishen Mehta to Its Board of Directors	07-01	CI
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell 3000E Index	06-30	CI
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Index	06-30	CI
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Index	06-30	CI
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell 3000E Value Index	06-30	CI
Piper Sandler Initiates Benitec Biopharma With Overweight Rating, $30 Price Target	06-13	MT
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-13	CI
Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	04-21	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	04-18	MT
Top Midday Gainers	04-18	MT
Top Premarket Gainers	04-18	MT
Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	04-18	CI
Benitec Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-13	CI
JMP Securities Adjusts Benitec Biopharma's Price Target to $8 From $6, Keeps Market Outperform Rating	01-24	MT
Benitec Biopharma Doses First Participant in Trial of Treatment for Oculopharyngeal Muscular Dystrophy	11-30	MT
Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	11-30	CI
Earnings Flash (BNTC) BENITEC BIOPHARMA Posts Q1 Revenue $0M	11-13	MT
Benitec Biopharma Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-13	CI
Certain Common Stock of Benitec Biopharma Inc. are subject to a Lock-Up Agreement Ending on 6-NOV-2023.	11-05	CI
Benitec Biopharma Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-21	CI
Sector Update: Health Care Stocks Gaining in Late Afternoon Trading	23-08-11	MT
Sector Update: Health Care	23-08-11	MT
Benitec Biopharma Completes $30.9 Million Public Offering	23-08-11	MT
Top Midday Gainers	23-06-26	MT

Chart Benitec Biopharma Inc.

Duration

Period

More charts

Company Profile

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Companyâs platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).

Sector

Biotechnology & Medical Research

Calendar

2024-09-17 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.48 AUD

Average target price

33.88 AUD

Spread / Average Target

+118.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENITEC BIOPHARMA INC.	+222.29%	97.52M
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+45.38%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research